Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. Februar 2017 08:05 ET | Quelle: Peregrine Pharmaceuticals Inc.

Recent Publication Highlights Proof-of-Concept Data Supporting the Diagnostic Potential of Phosphatidylserine-Positive Exosomes in Ovarian Cancer

TUSTIN, Calif., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high...
14. Juli 2016 16:05 ET | Quelle: Peregrine Pharmaceuticals Inc.

Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2016 and Recent Developments

-- Avid Contract Manufacturing Revenues Increased 66% to $44.4 Million with a Revenue Backlog of $68 Million Heading into Fiscal Year 2017 ---- Growing Biomanufacturing Demand Prompts Plans for Third...
14. Juli 2016 08:05 ET | Quelle: Peregrine Pharmaceuticals Inc.

Peregrine Licenses Novel Exosome-Based Cancer Detection and Monitoring Technology from UT Southwestern Medical Center

--New Technology Efficiently Builds on the Company’s Existing Phosphatidylserine (PS) Targeting Platform and Assay Development Capabilities-- --Stand Alone Program That Offers Significant...